title: c-Myc is necessary for DNA damage-induced apoptosis in the G(2) phase of the cell cycle.
abstract: The c-myc proto-oncogene encodes a transcription factor that participates in the regulation of cellular proliferation, differentiation, and apoptosis. Ectopic overexpression of c-Myc has been shown to sensitize cells to apoptosis. We report here that cells lacking c-Myc activity due to disruption of the c-myc gene by targeted homologous recombination are defective in DNA damage-initiated apoptosis in the G(2) phase of the cell cycle. The downstream effector of c-Myc is cyclin A, whose ectopic expression in c-myc(-/-) cells rescues the apoptosis defect. The kinetics of the G(2) response indicate that the induction of cyclin A and the concomitant activation of Cdk2 represent an early step during commitment to apoptosis. In contrast, expression of cyclins E and D1 does not rescue the apoptosis defect, and apoptotic processes in G(1) phase are not affected in c-myc(-/-) cells. These observations link DNA damage-induced apoptosis with cell cycle progression and implicate c-Myc in the functioning of a subset of these pathways.
authors: Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, Rhode Island 02912, USA.
authors: S
authors: S
authors: Adachi
authors: A J
authors: AJ
authors: Obaya
authors: Z
authors: Z
authors: Han
authors: N
authors: N
authors: Ramos-Desimone
authors: J H
authors: JH
authors: Wyche
authors: J M
authors: JM
authors: Sedivy
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis; D042846:CDC2-CDC28 Kinases; D002460:Cell Line; D002945:Cisplatin / Q000494:pharmacology; D003432:Cross-Linking Reagents / Q000494:pharmacology; D019925:Cyclin A / Q000378:metabolism; D019938:Cyclin D1 / Q000378:metabolism; D019927:Cyclin E / Q000378:metabolism; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases / Q000378:metabolism; D004249:DNA Damage; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005047:Etoposide / Q000494:pharmacology; D005434:Flow Cytometry; D016193:G1 Phase; D016195:G2 Phase; D015151:Immunoblotting; D007700:Kinetics; D016297:Mutagenesis, Site-Directed; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000502:physiology*; D051381:Rats; D011995:Recombination, Genetic; D013997:Time Factors; D019076:Transgenes
chemical_list: D003432:Cross-Linking Reagents; D019925:Cyclin A; D019927:Cyclin E; D004791:Enzyme Inhibitors; D019384:Nucleic Acid Synthesis Inhibitors; D016271:Proto-Oncogene Proteins c-myc; C113584:purvalanol B; D019938:Cyclin D1; D005047:Etoposide; D017346:Protein Serine-Threonine Kinases; D042846:CDC2-CDC28 Kinases; C495892:Cdk2 protein, rat; D051357:Cyclin-Dependent Kinase 2; D018844:Cyclin-Dependent Kinases; D000225:Adenine; D002945:Cisplatin